UCB announced today its consolidated half year 2009 financial results. The first half year of 2009 is marked by progress with clinical development, operational and financial performance, and by a record number of product launches.
This financial report coincides with a number of launches from UCB. In the US the Cimzia/RA has been launched, as has the Vimpat/Epilepsy, which has also been introduced in Europe along with Neupro/RLS and Newpro/new patients Parkinson’s disease.
“Our Half-Year Report 2009 records significant progress for UCB. With multiple product launches underway showing already promise, we at UCB now have the future in our hands,” said Roch Doliveux, Chief Executive Officer, UCB. “We are focusing on the successful commercialization of our major new products Cimzia, Vimpat and Neupro in order to bring benefit to patients living with severe disease. At the same time, we are striving for improved efficiency and more partnerships to strengthen our performance and to continue transforming UCB into the next generation biopharma leader.”
UCB have confirmed their outlook for 2009 is expected to reach between 3.1 and 3.3 billion euros.